Related Experiment Video
Updated: Sep 16, 2025
10:18
Real-Time, Semi-Automated Fluorescent Measurement of the Airway Surface Liquid pH of Primary Human Airway Epithelial Cells
Published on: June 13, 2019
7.5K
Feasibility of Treating Eosinophilic Chronic Rhinosinusitis Using Short-Chain Fatty Acids
Rikako Gozawa1, Yoshimasa Imoto1, Yuki Sonoda1
1Department of Otorhinolaryngology Head & Neck Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
The Laryngoscope
|July 11, 2025
Summary
Short-chain fatty acids (SCFAs) show potential in treating eosinophilic chronic rhinosinusitis (ECRS). Propionic acid, an SCFA, was found to suppress key inflammatory markers and reduce eosinophil survival, suggesting a therapeutic role.
Area of Science:
- Immunology
- Microbiology
- Otolaryngology
Background:
- Epithelial cell-derived cytokines are implicated in chronic rhinosinusitis with nasal polyps (CRSwNPs).
- Short-chain fatty acids (SCFAs), microbial metabolites, play a role in inflammation.
Purpose of the Study:
- To investigate the role of SCFAs in eosinophilic chronic rhinosinusitis (ECRS).
Main Methods:
- Quantitative real-time PCR analyzed gene expression of GPR41/FFAR3, GPR43/FFAR2, TSLP, IL-25, and IL-33 in nasal polyp tissues.
- Normal human bronchial epithelial (NHBE) cells were stimulated with poly(I:C) with or without SCFAs to measure TSLP.
- Immunohistochemistry assessed GPR41 in eosinophils and Eol-1 cells; Eol-1 cell viability with propionic acid was evaluated.
Main Results:
- GPR41 and GPR43 mRNA expression were significantly higher in ECRS nasal polyps (NPs).
- TSLP mRNA expression was elevated in ECRS-NPs, correlating with eosinophil counts.
- SCFAs (acetic, propionic, butyric acids) suppressed poly(I:C)-induced TSLP in NHBE cells; propionic acid reduced Eol-1 cell survival.
Conclusions:
- SCFAs, especially propionic acid, may offer a treatment strategy for ECRS.
- Propionic acid demonstrates potential by suppressing TSLP and eosinophils.
Related Concept Videos
01:24Cystic Fibrosis: Management
227
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
227
01:29Acute Respiratory Failure-V
212
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
212